Article Text

Download PDFPDF
Where next for cell-based therapy in ARDS
  1. Andrew James Boyle1,2,
  2. Cecilia M O’Kane1,
  3. Daniel Francis McAuley1,2
  1. 1 Centre for Experimental Medicine, Queen’s University Belfast, Belfast, UK
  2. 2 Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK
  1. Correspondence to Dr Daniel Francis McAuley, Centre for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UK; d.f.mcauley{at}qub.ac.uk

Statistics from Altmetric.com

Acute respiratory distress syndrome (ARDS) is a form of acute hypoxaemic respiratory failure that is characterised by non-cardiogenic pulmonary oedema which occurs as a consequence of the breakdown of the alveolar–capillary unit.1 ARDS impacts more than 10% of all intensive care unit admissions, and pneumonia is the most common risk factor for ARDS.2 Current standard of care aims to minimise iatrogenic lung injury from mechanical ventilation,3 4 while clinical trials of pharmacological therapies that have targeted the underlying mechanisms driving the development of ARDS have failed to show benefit.5

Beyond pharmacological therapies, much interest in this field has focused on mesenchymal stromal cells (MSCs) as a potential therapeutic option for ARDS.6 In the latest development towards a cell-based therapy for ARDS, Park et al report the use of an human ex vivo lung perfusion model of ARDS to investigate MSC-derived microvesicles (MVs) as a therapy for ARDS.7 MSCs are pluripotent cells that can be extracted from various sources including bone marrow, adipose tissue and umbilical cord. In ARDS they may represent an attractive therapy because of a broad range of potentially beneficial effects, including anti-inflammatory, pro-reparative and antimicrobial effects.8–10 Excessive host inflammation contributes to alveolar epithelial and capillary endothelial damage, and in this setting MSCs have immunomodulatory effects via the secretion of several anti-inflammatory compounds including Interleukin (IL) 10 and IL1 receptor antagonist. Loss of alveolar fluid clearance (AFC) in patients with ARDS contributes to alveolar flooding and is associated with increased hospital mortality.11 The delivery of MSCs to injured lungs restored AFC in a human ex vivo model of lung injury. This effect was in-part mediated by the secretion of keratinocyte growth factor (KGF), one of several soluble growth factors produced by MSCs.12 Approximately …

View Full Text

Footnotes

  • Contributors AJB wrote the initial draft, and CMO and DFM edited and completed the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests AJB declares no competing interest. DFM’s institution has received a grant from the Wellcome Trust for a clinical trial of MSCs in ARDS. Outside of the submitted work, DFM reports personal fees from consultancy for GlaxoSmithKline, SOBI, Peptinnovate, Boehringer Ingelheim and Bayer, funds to his institution from grants from the UK NIHR and others and from GlaxoSmithKline for undertaking bronchoscopy as part of a clinical trial. In addition, DFM has a patent application issued to his institution. CMO’s institution has received a grant from the Wellcome Trust for a clinical trial of MSCs in ARDS. Outside of the submitted work CMO reports that her spouse has received personal fees from consultancy for GlaxoSmithKline, SOBI, Peptinnovate, Boehringer Ingelheim and Bayer. CMO’s institution has also received funds from grants from the Northern Ireland Health and Social Care Research and Development office.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles